- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 211/20 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulfur atoms
Patent holdings for IPC class C07D 211/20
Total number of patents in this class: 68
10-year publication summary
|
9
|
4
|
4
|
1
|
2
|
4
|
1
|
4
|
1
|
2
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Prilenia Neurotherapeutics Ltd. | 89 |
6 |
| Boehringer Ingelheim International GmbH | 4642 |
4 |
| H. Lundbeck A/S | 1250 |
3 |
| Sanochemia Pharmazeutika GmbH | 36 |
3 |
| AstraZeneca AB | 2908 |
2 |
| Takeda Pharmaceutical Company Limited | 2705 |
2 |
| Global Blood Therapeutics, Inc. | 183 |
2 |
| Teva Pharmaceuticals International GmbH | 331 |
2 |
| Teva Pharmaceuticals USA, Inc. | 881 |
2 |
| Zentiva k.s. | 575 |
2 |
| ReNAgade Therapeutics Management Inc. | 47 |
2 |
| Bristol-myers Squibb Company | 4867 |
1 |
| Genentech, Inc. | 3994 |
1 |
| Syngenta Crop Protection AG | 6107 |
1 |
| Bayer Pharma AG | 1054 |
1 |
| The General Hospital Corporation | 4759 |
1 |
| Cellixbio Private Limited | 155 |
1 |
| Ciba Corporation | 15 |
1 |
| Cipla Limited | 465 |
1 |
| Dainippon Sumitomo Pharma Co., Ltd. | 190 |
1 |
| Other owners | 29 |